Luecking Hannes, Doerfler Arnd, Goelitz Philipp, Hoelter Philip, Engelhorn Tobias, Lang Stefan
Department of Neuroradiology, University of Erlangen-Nuremberg, Erlangen, Germany.
Interv Neuroradiol. 2020 Feb;26(1):38-44. doi: 10.1177/1591019919878551. Epub 2019 Oct 9.
Flow-diverter stents are well-established for the treatment of cerebral aneurysms. Flow Redirection Endoluminal Device differs from other flow-diverter stents by its dual-layer design and has proved equality to other devices in numerous short-term surveys. However, follow-up data covering substantially more than one year are still limited for this device. We present our long-term experience with Flow Redirection Endoluminal Device.
Seventy-eight patients harboring distal internal carotid artery (91%) or vertebrobasilar (9%) cerebral aneurysms treated with Flow Redirection Endoluminal Device with or without adjunctive coiling met the inclusion criteria. All cases were evaluated for aneurysm occlusion (according to Modified Raymond Roy Classification, MRRC), for flow-diverter stents patency and configuration and for procedure- and device-related morbidity and mortality.
Mean follow-up interval was 36.9 ± 9.5 months (<30 months: n = 18; 31-42 months: n = 31; >42 months: n = 24). Total and subtotal aneurysm occlusion after six months was assessed in 92.0% (MRRC = 77.3%, MRRC = 14.7%, MRRC =2.7%, MRRC = 4.1%) and increased to 95.9% (MRRC = 90.5%, MRRC = 5.4%, MRRC = 2.7%). There was one case of aneurysm growth requiring early re-treatment. Procedure-related morbidity was observed in three cases (3.8%; one transient hemiparesis, one suspected foreign-body reaction, and one micro-wire perforation). There was no procedure- or device-related mortality. In-stent stenosis due to intimal hyperplasia was observed in two cases and fish-mouthing in three cases.
Our long-term data covering two to five years after flow diversion confirm that Flow Redirection Endoluminal Device is a safe and effective device for the treatment of cerebral aneurysms with progressive high aneurysm occlusion rates; recurrence rates were very low. Overall device-related morbidity was low and was not observed later than six months after intervention.
血流导向支架在脑动脉瘤治疗中已得到广泛应用。血流导向腔内装置(Flow Redirection Endoluminal Device)因其双层设计与其他血流导向支架不同,且在众多短期研究中已证明其与其他装置效果相当。然而,该装置超过一年的随访数据仍然有限。我们展示了我们使用血流导向腔内装置的长期经验。
78例患有颈内动脉远端(91%)或椎基底动脉(9%)脑动脉瘤的患者接受了血流导向腔内装置治疗,部分患者联合使用了弹簧圈栓塞,均符合纳入标准。所有病例均评估动脉瘤闭塞情况(根据改良雷蒙德·罗伊分类法,MRRC)、血流导向支架的通畅性和形态,以及与手术和装置相关的发病率和死亡率。
平均随访时间为36.9±9.5个月(<30个月:n = 18;31 - 42个月:n = 31;>42个月:n = 24)。6个月时评估的动脉瘤完全和次全闭塞率为92.0%(MRRC = 77.3%,MRRC = 14.7%,MRRC = 2.7%,MRRC = 4.1%),并增至95.9%(MRRC = 90.5%,MRRC = 5.4%,MRRC = 2.7%)。有1例动脉瘤增大需要早期再次治疗。观察到3例与手术相关的并发症(3.8%;1例短暂性偏瘫、1例疑似异物反应和1例微导丝穿孔)。无手术或装置相关死亡。观察到2例因内膜增生导致的支架内狭窄和3例鱼嘴样改变。
我们关于血流导向术后两到五年的长期数据证实,血流导向腔内装置是一种安全有效的治疗脑动脉瘤的装置,动脉瘤闭塞率逐步提高;复发率非常低。总体与装置相关的发病率较低,且在干预后6个月内未观察到。